Diurnal Group could learn this week whether the European Medicines Agency will recommend pan-EU marketing authorization for Chronocort (modified-release hydrocortisone), the UK company’s replacement therapy for the rare condition congenital adrenal hyperplasia (CAH).
Chronocort is not yet approved in any country. It is among the new medicines that are listed on the








